May 22, 2020 / 11:21 AM / 9 days ago

BRIEF-Kitov Announces U.S. FDA Acceptance Of Investigational NDA To Conduct Phase 1/2 Clinical Trial Of NT219 In Multiple Types Of Advanced Cancer Patients

May 22 (Reuters) - Kitov Pharma Ltd:

* KITOV ANNOUNCES U.S. FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION TO CONDUCT PHASE 1/2 CLINICAL TRIAL OF NT219 IN MULTIPLE TYPES OF ADVANCED CANCER PATIENTS

* KITOV - PRIMARY OBJECTIVES OF PHASE 1/2 TRIAL ARE TO IDENTIFY APPROPRIATE DOSE TO BE STUDIED IN PHASE 2, ESTABLISH PRELIMINARY EFFICACY OF NT219 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below